drugset / Trial / NCT07202364
A Study of YL202 in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Timeline
- Start
- 2025-08-04
- Primary completion
- 2026-08-31
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YL202 | Unknown | 1.6 mg | Intravenous |